Scientists move closer to bio-engineered bladders
1 August 2007
Researchers at the University of York are using an understanding of the special cells that line the bladder to develop ways of restoring continence to patients with serious bladder conditions, including cancer. The research, highlighted in the quarterly magazine of the Biotechnology and Biological Sciences Research Council (BBSRC) this week, is looking at urothelial cells. These are the specialised lining cells of the bladder that enable it to retain urine. The cells have a very low turnover rate, but scientists have found that if the bladder is damaged, the urothelial cells are able to rapidly re-grow to repair the wound. The researchers hope to harness this property to engineer new bladders.
The York researchers have developed a series of models that mean they can study human urothelial cells in the laboratory. Of these models, the most important is their development of a urothelial cell sheet that functions as it would in the bladder. When the researchers create a wound in this model, the cells regenerate to repair the damage – just as they would in the body.
Pharmaceutical companies should soon be able to use the research models to test therapies for the bladder, but the longer term aim for this research is to help patients who have lost bladder function or have had all or part of their bladder removed because of cancer.
Research leader, Professor Jenny Southgate, explains: “The models we have developed mean that we have been able to examine how urothelial cells in the bladder self-renew to cope with injury.
“With this basic understanding of how the cells work, we are moving towards being able to engineer new bladders. Currently, substitute bladders can be created by using a section of the patient’s bowel, but this can lead to complications, as the bowel does not have the same urine-holding properties as urothelial cells. One solution could be to use laboratory-grown urothelial cells to line a section of bowel.”
The hope in the long term is that collaborative research to combine Professor Southgate’s work with biomaterial studies at the Universities of Durham and Leeds could mean engineered bladder tissue ready for transplantation.
Professor Southgate, who is Director of the Jack Birch Unit for Molecular Carcinogenesis, in the University of York's Department of Biology said: “Our most exciting work moving forward is to develop natural and synthetic biomaterials that could be combined with regenerating urothelial cells. This has the potential to produce viable bladder tissue for transplant into patients who need replacement bladders.”
The York research highlights the importance of basic biology research in underpinning medical advances. Professor Nigel Brown, BBSRC Director of Science and Technology, commented: “Fundamental bioscience research forms the foundation for much of the medical advances we have today and hope for in the future. We need a solid understanding of how our bodies work and maintain themselves before we can understand what goes wrong when they become diseased and how the disease can be treated.”
Notes to editors
The research described feature in the July 2007 issue of Business, the quarterly research highlights magazine of the Biotechnology and Biological Sciences Research Council.
The research is funded by BBSRC and the team also receive support from the Engineering and Physical Sciences Research Council.
Chronic urinary incontinence due to bladder disease or dysfunction can affect both paediatric and adult populations. A radical cystectomy can be one way of dealing with invasive bladder cancer and involves the complete removal of a patient’s bladder. Dealing with the loss of bladder function can involve urostomy, continent urinary diversion or bladder reconstruction from a section of bowel.
The Jack Birch Unit for Molecular Carcinogenesis, in the University of York's Department of Biology, was opened in 1992, funded by the generosity of the late Jack Birch, OBE and York Against Cancer. The focus of the Research Unit is the investigation of human carcinomas, with special emphasis on bladder cancer, the fifth most common adult cancer.
The Biotechnology and Biological Sciences Research Council (BBSRC) is the UK funding agency for research in the life sciences. Sponsored by Government, BBSRC annually invests around £380 million in a wide range of research that makes a significant contribution to the quality of life for UK citizens and supports a number of important industrial stakeholders including the agriculture, food, chemical, healthcare and pharmaceutical sectors. http://www.bbsrc.ac.uk
Professor Jenny Southgate, University of York
tel: 01904 328705
David Garner, University of York
tel: 01904 432153
Matt Goode, Head of External Relations
tel: 01793 413299
fax: 01793 413382
Tracey Jewitt, Media Officer
tel: 01793 414694
fax: 01793 413382